Similarly, the SERT promoter polymorphism has been reported to predict response to alosetron in IBS-D withsl genotype showing reduced responsiveness27, but this was not confirmed in a larger trial with ondansetron28. The gene discussed is SLC6A4; the disease is irritable bowel syndrome.